Shuttle Pharmaceuticals Holdings (SHPH) Share-based Compensation (2021 - 2026)
Shuttle Pharmaceuticals Holdings' (SHPH) quarterly Share-based Compensation came in at $33334.0 in Q1 2026, up 416575.0% year-on-year from N/an in Q1 2025, and down 84.48% quarter-over-quarter from $214750.0 in Q4 2025.
Shuttle Pharmaceuticals Holdings (SHPH) Share-based Compensation (2021 - 2026) Analysis & Trends
Shuttle Pharmaceuticals Holdings' Share-based Compensation history runs 6 years deep, the most recent figure standing at $33334.0 for Q1 2026.
- On a quarterly basis, Share-based Compensation rose 416575.0% year-over-year to $33334.0 in Q1 2026; TTM through Mar 2026 was $429255.0, a 189.44% increase from a year earlier, with the FY2025 full-year figure at $932967.0, up 3.66% from the prior year.
- Share-based Compensation retreated to $33334.0 in Q1 2026 per SHPH's latest filing, from $214750.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $300000.0 in Q2 2023 and bottomed at -$119186.0 in Q4 2022.
- The 5-year median for Share-based Compensation is $46853.0 (2025), against an average of $79038.8.
- Across the five-year window, Share-based Compensation plunged 121.97% in 2022 and soared 416575.0% in 2026, its largest moves.
- Year by year, Share-based Compensation stood at -$119186.0 in 2022, then jumped by 172.59% to $86522.0 in 2023, then sank by 63.18% to $31858.0 in 2024, then soared by 574.09% to $214750.0 in 2025, then sank by 84.48% to $33334.0 in 2026.
- Per Business Quant, the three latest SHPH Share-based Compensation figures stand at $33334.0 (Q1 2026), $214750.0 (Q4 2025), and $134318.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Shuttle Pharmaceuticals Holdings | 120,186.04 | 120,186.04 | - | 33,334.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33,334.00 |
| Mar 31, 2026 | 33,334.00 |
| Dec 31, 2025 | 214,750.00 |
| Dec 31, 2025 | 214,750.00 |
| Sep 30, 2025 | 134,318.00 |
| Sep 30, 2025 | 134,318.00 |
| Jun 30, 2025 | 46,853.00 |
| Jun 30, 2025 | 46,853.00 |
| Mar 31, 2025 | 8.00 |
| Mar 31, 2025 | 8.00 |
| Dec 31, 2024 | 31,858.00 |
| Dec 31, 2024 | 31,858.00 |
| Sep 30, 2024 | 45,275.00 |
| Sep 30, 2024 | 45,275.00 |
| Jun 30, 2024 | 71,162.00 |
| Jun 30, 2024 | 71,162.00 |
| Mar 31, 2024 | 111,449.00 |
| Mar 31, 2024 | 111,449.00 |
| Dec 31, 2023 | 86,522.00 |
| Dec 31, 2023 | 86,522.00 |